Literature DB >> 28629988

4'-Azidocytidine (R1479) inhibits henipaviruses and other paramyxoviruses with high potency.

Anne L Hotard1, Biao He2, Stuart T Nichol1, Christina F Spiropoulou3, Michael K Lo4.   

Abstract

The henipaviruses Nipah virus and Hendra virus are highly pathogenic zoonotic paramyxoviruses which have caused fatal outbreaks of encephalitis and respiratory disease in humans. Despite the availability of a licensed equine Hendra virus vaccine and a neutralizing monoclonal antibody shown to be efficacious against henipavirus infections in non-human primates, there remains no approved therapeutics or vaccines for human use. To explore the possibility of developing small-molecule nucleoside inhibitors against henipaviruses, we evaluated the antiviral activity of 4'-azidocytidine (R1479), a drug previously identified to inhibit flaviviruses, against henipaviruses along with other representative members of the family Paramyxoviridae. We observed similar levels of R1479 antiviral activity across the family, regardless of virus genus. Our brief study expands the documented range of viruses susceptible to R1479, and provides the basis for future investigation and development of 4'-modified nucleoside analogs as potential broad-spectrum antiviral therapeutics across both positive and negative-sense RNA virus families. Published by Elsevier B.V.

Entities:  

Keywords:  4′-Azidocytidine; Antiviral; Henipavirus; Nipah virus; Nucleoside analog

Mesh:

Substances:

Year:  2017        PMID: 28629988      PMCID: PMC5648002          DOI: 10.1016/j.antiviral.2017.06.011

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  30 in total

1.  Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients.

Authors:  David R Nelson; Stefan Zeuzem; Pietro Andreone; Peter Ferenci; Robert Herring; Donald M Jensen; Patrick Marcellin; Paul J Pockros; Maribel Rodríguez-Torres; Lorenzo Rossaro; Vinod K Rustgi; Thomas Sepe; Mark Sulkowski; Isaac R Thomason; Eric M Yoshida; Anna Chan; George Hill
Journal:  Ann Hepatol       Date:  2012 Jan-Feb       Impact factor: 2.400

2.  Dual myxovirus screen identifies a small-molecule agonist of the host antiviral response.

Authors:  Dan Yan; Stefanie A Krumm; Aiming Sun; David A Steinhauer; Ming Luo; Martin L Moore; Richard K Plemper
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

3.  Rescue of wild-type mumps virus from a strain associated with recent outbreaks helps to define the role of the SH ORF in the pathogenesis of mumps virus.

Authors:  Pei Xu; Zhuo Li; Dengyun Sun; Yuan Lin; Jianguo Wu; Paul A Rota; Biao He
Journal:  Virology       Date:  2011-06-14       Impact factor: 3.616

Review 4.  Henipavirus pathogenesis and antiviral approaches.

Authors:  Cyrille Mathieu; Branka Horvat
Journal:  Expert Rev Anti Infect Ther       Date:  2015-01-29       Impact factor: 5.091

Review 5.  Molecular virology of the henipaviruses.

Authors:  Paul A Rota; Michael K Lo
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

6.  Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection.

Authors:  L K Hallak; D Spillmann; P L Collins; M E Peeples
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

7.  Live-attenuated measles virus vaccine targets dendritic cells and macrophages in muscle of nonhuman primates.

Authors:  Linda J Rennick; Rory D de Vries; Thomas J Carsillo; Ken Lemon; Geert van Amerongen; Martin Ludlow; D Tien Nguyen; Selma Yüksel; R Joyce Verburgh; Paula Haddock; Stephen McQuaid; W Paul Duprex; Rik L de Swart
Journal:  J Virol       Date:  2014-12-03       Impact factor: 5.103

8.  Use of monoclonal antibodies against Hendra and Nipah viruses in an antigen capture ELISA.

Authors:  Cheng-Feng Chiang; Michael K Lo; Paul A Rota; Christina F Spiropoulou; Pierre E Rollin
Journal:  Virol J       Date:  2010-06-03       Impact factor: 4.099

9.  Therapeutic treatment of Nipah virus infection in nonhuman primates with a neutralizing human monoclonal antibody.

Authors:  Thomas W Geisbert; Chad E Mire; Joan B Geisbert; Yee-Peng Chan; Krystle N Agans; Friederike Feldmann; Karla A Fenton; Zhongyu Zhu; Dimiter S Dimitrov; Dana P Scott; Katharine N Bossart; Heinz Feldmann; Christopher C Broder
Journal:  Sci Transl Med       Date:  2014-06-25       Impact factor: 17.956

10.  Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals.

Authors:  Brian H Bird; César G Albariño; Amy L Hartman; Bobbie Rae Erickson; Thomas G Ksiazek; Stuart T Nichol
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

View more
  15 in total

1.  Potent in vitro activity of β-D-4'-chloromethyl-2'-deoxy-2'-fluorocytidine against Nipah virus.

Authors:  Michael K Lo; Franck Amblard; Mike Flint; Payel Chatterjee; Mahesh Kasthuri; Chengwei Li; Olivia Russell; Kiran Verma; Leda Bassit; Raymond F Schinazi; Stuart T Nichol; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2020-01-11       Impact factor: 5.970

Review 2.  Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses.

Authors:  Luděk Eyer; Radim Nencka; Erik de Clercq; Katherine Seley-Radtke; Daniel Růžek
Journal:  Antivir Chem Chemother       Date:  2018 Jan-Dec

3.  Initiation, extension, and termination of RNA synthesis by a paramyxovirus polymerase.

Authors:  Paul C Jordan; Cheng Liu; Pauline Raynaud; Michael K Lo; Christina F Spiropoulou; Julian A Symons; Leo Beigelman; Jerome Deval
Journal:  PLoS Pathog       Date:  2018-02-09       Impact factor: 6.823

Review 4.  The evolution of antiviral nucleoside analogues: A review for chemists and non-chemists. Part II: Complex modifications to the nucleoside scaffold.

Authors:  Mary K Yates; Katherine L Seley-Radtke
Journal:  Antiviral Res       Date:  2018-12-08       Impact factor: 10.103

5.  Phosphorylated abacavir analogue (ABC-1) has ameliorative action against Newcastle disease virus induced pathogenesis in chicken.

Authors:  K A Suresh; K C Venkata Subbaiah; C Thirunavukkarasu; S Chennakesavulu; A Rachamallu; Naga Raju Chamarti; Rajendra Wudayagiri; Lokanatha Valluru
Journal:  Biotechnol Appl Biochem       Date:  2019-10-23       Impact factor: 2.431

6.  Favipiravir (T-705) protects against Nipah virus infection in the hamster model.

Authors:  Brian E Dawes; Birte Kalveram; Tetsuro Ikegami; Terry Juelich; Jennifer K Smith; Lihong Zhang; Arnold Park; Benhur Lee; Takashi Komeno; Yousuke Furuta; Alexander N Freiberg
Journal:  Sci Rep       Date:  2018-05-15       Impact factor: 4.379

7.  Susceptibility of paramyxoviruses and filoviruses to inhibition by 2'-monofluoro- and 2'-difluoro-4'-azidocytidine analogs.

Authors:  Michael K Lo; Paul C Jordan; Sarah Stevens; Yuen Tam; Jerome Deval; Stuart T Nichol; Christina F Spiropoulou
Journal:  Antiviral Res       Date:  2018-03-27       Impact factor: 5.970

Review 8.  Recent advances in the understanding of Nipah virus immunopathogenesis and anti-viral approaches.

Authors:  Rodolphe Pelissier; Mathieu Iampietro; Branka Horvat
Journal:  F1000Res       Date:  2019-10-16

Review 9.  Antivirals in medical biodefense.

Authors:  J J Bugert; F Hucke; P Zanetta; M Bassetto; A Brancale
Journal:  Virus Genes       Date:  2020-02-19       Impact factor: 2.198

10.  NipahVR: a resource of multi-targeted putative therapeutics and epitopes for the Nipah virus.

Authors:  Amit Kumar Gupta; Archit Kumar; Akanksha Rajput; Karambir Kaur; Showkat Ahmed Dar; Anamika Thakur; Kirti Megha; Manoj Kumar
Journal:  Database (Oxford)       Date:  2020-01-01       Impact factor: 3.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.